EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrates for Direct Oral Anticoagulant Reversal Prior to Urgent Surgery or Invasive Procedure

Katie Sherman, Christopher Leong, Kendall Mores

Journal of Acute Care Pharmacotherapy · 28.02.2026 · 2 (1)

DOI: 10.67122/001c.156018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Acute Care Pharmacotherapy, online erschienen am 28.02.2026. Verfasst von Katie Sherman und 2 weiteren Autor:innen. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Andexanet alfa is a modified factor-Xa decoy protein labeled for reversal of direct oral anticoagulants (DOACs) rivaroxaban and apixaban. Fast-track approval stemming from the single-arm ANNEXA-4 trial left questions about efficacy in specific populations, particularly surgical, as patients undergoing surgery or invasive procedures within 12 hours of randomization were excluded. Additionally, the ANNEXA-S trial intended to fill this gap was terminated early for futility. More information is needed to evaluate andexanet alfa alongside alternate reversal strategies, such as 4-factor prothrombin complex concentrates (4F-PCCs), in this population.

Objectives

To determine if there is a significant difference in hemostatic effectiveness between andexanet alfa and 4F-PCCs when used for DOAC reversal in the setting of emergent surgery or procedure.

Methods

This single-center, retrospective study included patients who received andexanet alfa or 4F-PCCs within 24 hours of emergent surgery or procedure. The primary outcome was adequate hemostasis, defined as a composite of stable hemoglobin and lack of additional coagulation factors or transfusions administered at 48 hours post-reversal. Secondary outcomes included repeat reversal administration, type and quantification of transfusions, 30-day incidence of thrombosis, and 30-day mortality.

Results

Twenty-nine patients were included; 14 received andexanet alfa and 15 received 4F-PCCs. The majority of patients underwent general surgery, most commonly exploratory laparotomy. No statistically significant difference was observed for the primary composite outcome; however, a statistically significant difference was observed in the number of patients treated with andexanet alfa who required subsequent administration of 4F-PCCs or fresh frozen plasma (FFP) (50% vs. 26.7%, p=0.196).

Conclusion

Periprocedural or perioperative reversal with andexanet alfa may result in an increased need for additional reversal or transfusions compared to 4F-PCCs. Larger prospective comparator trials with diverse procedure types are needed to confirm these findings.

Zitieren

APA

Sherman, K., Leong, C., & Mores, K. (2026). Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrates for Direct Oral Anticoagulant Reversal Prior to Urgent Surgery or Invasive Procedure. Journal of Acute Care Pharmacotherapy, 2(1). https://doi.org/10.67122/001c.156018

Vancouver

Sherman K, Leong C, Mores K. Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrates for Direct Oral Anticoagulant Reversal Prior to Urgent Surgery or Invasive Procedure. Journal of Acute Care Pharmacotherapy. 2026;2(1). doi:10.67122/001c.156018

BibTeX
@article{Sherman2026,
  author = {Sherman, Katie and Leong, Christopher and Mores, Kendall},
  title = {Andexanet Alfa versus 4-Factor Prothrombin Complex Concentrates for Direct Oral Anticoagulant Reversal Prior to Urgent Surgery or Invasive Procedure},
  journal = {Journal of Acute Care Pharmacotherapy},
  year = {2026},
  volume = {2},
  number = {1},
  doi = {10.67122/001c.156018}
}
Kostenlos starten →